Loading...
•
Jun 30, 2025
Iovance Q2 2025 Earnings Report
Iovance Biotherapeutics reported its financial results and corporate updates for the second quarter and first half of 2025.
Key Takeaways
Iovance Biotherapeutics reported strong product revenue growth in Q2 2025, primarily driven by the U.S. launch of Amtagvi, which surpassed 100 patients treated in the quarter. The company also announced a strategic restructuring to extend its cash runway into Q4 2026 and reiterated its full-year 2025 total product revenue guidance.
Total product revenue reached $60.0 million in Q2 2025, a 93% increase year-over-year.
Amtagvi sales in the U.S. were $54.1 million, with over 100 commercial patients treated.
A strategic restructuring is expected to yield over $100 million in annual cost savings and extend the cash runway into Q4 2026.
Full-year 2025 total product revenue guidance of $250 million to $300 million was reiterated.
Revenue by Segment
Forward Guidance
Iovance Biotherapeutics expects continued growth in total product revenue for the full year 2025 and beyond, driven by Amtagvi adoption and Proleukin sales. The company is also focused on expanding Amtagvi's market reach globally and advancing its TIL cell therapy pipeline.
Positive Outlook
- Reiterated full-year 2025 total product revenue guidance of $250 million to $300 million.
- Expected first ex-U.S. regulatory approval for Amtagvi in Canada imminently, with commercial launch preparation.
- Anticipated Amtagvi approval in the UK, Australia, and Switzerland in 2026.
- Continued strong momentum for the registrational TILVANCE-301 trial for Amtagvi in combination with pembrolizumab in frontline advanced melanoma.
- Expected over $100 million in annual cost savings from strategic restructuring, extending cash runway into Q4 2026.
Challenges Ahead
- Withdrawal of Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for Amtagvi.
- Net cash burn for the next four quarters through Q2 2026 is expected to be less than $245 million, excluding one-time restructuring charges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...